<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thromboembolism in children with cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thromboembolism in children with cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thromboembolism in children with cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Uma H Athale, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet YK Yang, MBBS, MRCPCH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anthony KC Chan, MBBS, FRCPC, FRCPath</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Children with cancer are at increased risk for thrombosis and thromboembolism (TE) compared with the general pediatric population. The following discussion will review the incidence, risk factors, evaluation, prevention, and management of TE in children with cancer.</p><p>The pathogenesis, clinical manifestations, diagnosis, and treatment of TE in the general pediatric population and newborns are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5912.html" rel="external">"Neonatal thrombosis: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Although there are few prospective studies that directly compare the incidence of TE in children with cancer with the general pediatric population, evidence from registries clearly demonstrates that children with cancer are more likely to develop TE than those without cancer. In studies of children with cancer, reported rates of TE range from 4 to 8 percent [<a href="#rid1">1,2</a>]. This is considerably higher than in hospitalized children without cancer (which is approximately 20 to 60 per 10,000). (See  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis", section on 'Incidence'</a>.)</p><p>Several studies have shown that the incidence of TE in pediatric cancer patients has increased since the late 20<sup>th</sup> century [<a href="#rid3">3,4</a>]. This may be related to increased detection of TE due to more sensitive and more frequent testing and/or increased use of prothrombotic interventions (eg, central venous catheters [CVCs]).</p><p>The rates of TE vary for different types of pediatric malignancies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute lymphocytic leukemia (ALL)</strong> – In the available reports, rates of TE in children with ALL ranged from 3 to 15 percent [<a href="#rid1">1,5-8</a>]. Thrombotic events in this population can include deep vein thrombosis, cerebral sinovenous thrombosis, and pulmonary embolism. Reported risk factors for TE in children with ALL include [<a href="#rid1">1,5-9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age (adolescents are at higher risk than young children)</p><p class="bulletIndent2"><span class="glyph">•</span>T cell immunophenotype</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with asparaginase</p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant use of steroids</p><p class="bulletIndent2"><span class="glyph">•</span>Use of anthracycline</p><p class="bulletIndent2"><span class="glyph">•</span>Presence of a CVC</p><p class="bulletIndent2"><span class="glyph">•</span>Inherited thrombophilia</p><p class="bulletIndent2"><span class="glyph">•</span>Non-O blood group </p><p class="bulletIndent2"><span class="glyph">•</span>Obesity</p><p></p><p class="bulletIndent1">Thrombosis in children undergoing treatment for ALL is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Remission induction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute myeloid leukemia (AML)</strong> –<strong> </strong>Reported rates of TE in children with AML range from 4 to 6 percent [<a href="#rid1">1,2,4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoma</strong> – Reported rates of TE in children with lymphoma range from 5 to 12 percent [<a href="#rid1">1,2,4,5,10</a>]. In children with lymphoma, TE is more likely if there is a mediastinal mass, CVC, and/or peripherally inserted central catheter [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Solid tumors</strong> – The overall reported rate of TE in children with solid tumors ranges from 12 to 19 percent [<a href="#rid1">1,4,12-15</a>]. Proposed risk factors associated with thrombosis in children with solid tumors include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presence of a CVC [<a href="#rid1">1,10,12-19</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Age &gt;10 years [<a href="#rid4">4,12,14,15,20</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Type of tumor (eg, children with Ewing sarcoma are reported to have a greater chance of a TE) [<a href="#rid1">1,4,12,14,15</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Site of cancer either by direct invasion of the vessels (eg, Wilms tumor or hepatoblastoma) or by vessel compression (eg, mediastinal mass in lymphoma) [<a href="#rid21">21</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Metastatic disease [<a href="#rid4">4,14</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Prothrombotic defects [<a href="#rid18">18,20,22</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Obesity [<a href="#rid2">2</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Type of therapy (surgical intervention, radiation, and chemotherapeutic agents like anthracyclines and platinum were associated with significantly higher risk of TE) [<a href="#rid2">2</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system (CNS) tumors</strong> – TE is an uncommon event in children with CNS tumors compared with other types of cancer. Reported rates of TE in pediatric patients with CNS tumors ranged from 0.5 to 3 percent [<a href="#rid1">1,2,5,19,23</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In children with cancer, clinical manifestations of TE are similar to those seen in children without malignancy and vary depending on both the location and extension of the thrombus, acuity of the event, and age of the patient [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Central venous catheter (CVC)-related TE is by far the most common scenario, many of which are located in the upper venous system [<a href="#rid18">18</a>]. Non-CVC-related TE can occur in any venous system but most commonly presents in the lower extremities, especially in the iliac, femoral, and/or popliteal veins. Thrombosis may also develop in the central nervous system (CNS), lung, liver, and kidney. CNS thromboses can include arterial ischemic stroke or cerebral sinovenous thrombosis (CVT). CVT is most commonly seen in patients with acute lymphocytic leukemia. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"</a>.). </p><p>Asymptomatic and incidental thromboses are sometimes detected when surveillance imaging studies are performed for monitoring the child's malignancy. (See <a class="local">'Asymptomatic right atrial thrombosis'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>In children with cancer, the presentation of a thrombotic event may be complicated or confused by other cancer-associated problems with similar signs and symptoms. For example, a headache due to cerebral sinovenous thrombosis may be attributed to intrathecal chemotherapy. As a result, making the diagnosis may be challenging and/or delayed. Hence, a high index of suspicion is essential for earlier diagnosis of thrombosis in children with cancer.</p><p>The diagnostic approach of a thrombosis in the child with cancer is the same as in children without malignancy and is dependent upon the clinical findings and likely site of involvement. Diagnosis of venous thrombosis, thromboembolism, cerebral sinovenous thrombosis, and stroke are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6214.html" rel="external">"Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'Urgent evaluation'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Anticoagulation therapy in children with cancer is challenging because these children are at risk for both thrombosis and bleeding due to chemotherapy-related thrombocytopenia and coagulopathy. The management of TE in this setting must balance the risk of thrombosis progression or recurrence with the increased risk of bleeding due to anticoagulation therapy. In addition, children with cancer are more likely to undergo invasive procedures (eg, lumbar puncture, bone marrow aspiration and biopsy, and surgical procedures), which may result in bleeding or clinically significant bleeding.</p><p>Evidence-based guidelines for the management of TE in children with cancer are lacking [<a href="#rid25">25</a>]. Data are available from studies in the general pediatric population and in adults with cancer [<a href="#rid26">26-36</a>]; however, neither provide the information for optimal management for children with cancer. This is, in part, due to the following differences among the three groups:</p><p class="bulletIndent1"><span class="glyph">●</span>Age-related hemostasis between children and adults</p><p class="bulletIndent1"><span class="glyph">●</span>Biology of adult and pediatric malignancies, and the difference in anticancer treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Risks of bleeding and thrombosis in children with cancer and the general pediatric population</p><p></p><p>As a result, management for TE in children with cancer is primarily based upon the expert interpretation of the available data in general pediatrics and adult cancer patients as well as clinical experience.</p><p class="headingAnchor" id="H710769483"><span class="h2">Whom to treat</span><span class="headingEndMark"> — </span>In the absence of an obvious contraindication for anticoagulation therapy (eg, active bleeding), anticoagulation therapy should be started in children with cancer and symptomatic TE.</p><p class="headingAnchor" id="H11"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>Low molecular weight heparin (LMWH) is generally the preferred agent for treatment of cancer-associated TE in children [<a href="#rid34">34</a>]. LMWH has several advantages over <a class="drug drug_pediatric" data-topicid="13349" href="/d/drug information/13349.html" rel="external">unfractionated heparin</a> and <a class="drug drug_pediatric" data-topicid="12886" href="/d/drug information/12886.html" rel="external">warfarin</a>, as outlined in the table  (<a class="graphic graphic_table graphicRef114581" href="/d/graphic/114581.html" rel="external">table 1</a>). LMWH is also preferred over direct acting oral anticoagulants (DOACs) in this population because there is greater experience with LMWH and there are few data on the use of DOACs in pediatric cancer patients. However, ongoing studies are evaluating DOACs in this population. Additional detail regarding the advantages and disadvantages of different anticoagulant agents in children are provided separately. (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Anticoagulant agents'</a>.)</p><p>The dose of LMWH used to treat TE in children with cancer is similar to that used in the general pediatric population  (<a class="graphic graphic_table graphicRef64075" href="/d/graphic/64075.html" rel="external">table 2</a>) [<a href="#rid31">31</a>].  </p><p>Dose adjustment and other precautions are necessary in children with severe thrombocytopenia, as discussed below. (See <a class="local">'Management of anticoagulation in patients with thrombocytopenia'</a> below.)</p><p>Due to the risk of bleeding, LMWH therapy should be withheld prior to invasive procedures (eg, lumbar puncture, epidural procedure, or surgery). In our practice, the last dose of LMWH is usually given 24 hours before a procedure. We do not routinely measure anti-Xa before procedures. To be cautious, one may do a trough anti-Xa level at the first time LMWH is being held for invasive procedures. LMWH could be restarted 12 to 24 hours after the invasive procedures. </p><p>Additional details regarding the use of LMWH in children are provided separately. (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Low molecular weight heparin'</a>.)</p><p>Studies are underway to evaluate the safety and efficacy of DOACs (eg, <a class="drug drug_pediatric" data-topicid="127822" href="/d/drug information/127822.html" rel="external">rivaroxaban</a>, <a class="drug drug_pediatric" data-topicid="132189" href="/d/drug information/132189.html" rel="external">dabigatran</a>, and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>) in pediatric patients with cancer [<a href="#rid37">37</a>]. Rivaroxaban and dabigatran are approved for use in children. However, data on the use of these agents in children with cancer are very limited. The use of DOACs in the broader pediatric population is discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Direct oral anticoagulants'</a>.)</p><p>The efficacy of <a class="drug drug_pediatric" data-topicid="127822" href="/d/drug information/127822.html" rel="external">rivaroxaban</a> in the pediatric cancer population is supported by a subgroup analysis of the EINSTEIN-Jr trial, which was a randomized trial in which children with venous TE were randomly assigned to three months of rivaroxaban therapy or a standard anticoagulant (LMWH or <a class="drug drug_pediatric" data-topicid="12886" href="/d/drug information/12886.html" rel="external">warfarin</a>) [<a href="#rid38">38</a>]. Of the 500 children enrolled in the trial, 56 had cancer (hematologic malignancy in 64 percent, solid tumor in 36 percent). In these 56 patients, follow-up imaging after treatment showed resolved or improved thrombus in most patients regardless of the assigned treatment (80 percent in the rivaroxaban group, 75 percent in the standard care group). No patients in either group experienced major bleeding or recurrent TE. Additional details of the EINSTEIN-Jr trial are discussed separately. (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Efficacy'</a>.)</p><p>In a retrospective study of 16 children and adolescents with cancer-associated TE who were treated with <a class="drug drug_pediatric" data-topicid="127822" href="/d/drug information/127822.html" rel="external">rivaroxaban</a>, three patients (19 percent) experienced recurrent TE, one patient experienced major bleeding, and two patients (12 percent) experienced nonmajor clinically relevant bleeding over a median treatment duration of seven months [<a href="#rid39">39</a>]. The higher incidence of bleeding and TE recurrence in this study as compared with EINSTEIN-Jr may be explained, at least in part, by the longer duration of treatment and follow-up. In addition, one-third of the patients in this study had relapsed or refractory malignancy. </p><p class="headingAnchor" id="H3459595271"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The usual duration of anticoagulation for treatment of TE in pediatric patients with cancer is at least three months. Extended anticoagulation may be warranted if there are ongoing clinically important thrombotic risk factors (eg, use of asparaginase), as discussed below. (See <a class="local">'Prevention of recurrent thrombosis'</a> below.) </p><p class="headingAnchor" id="H14"><span class="h2">Management of anticoagulation in patients with thrombocytopenia</span><span class="headingEndMark"> — </span>Thrombocytopenia is common in children undergoing treatment for cancer. Children with platelet counts &lt;30,000/microL are at increased risk of bleeding complications with LMWH treatment, particularly when full treatment doses are used.</p><p>Evidence is lacking on how to best manage anticoagulation therapy in this setting. In our practice, during the initial acute management, we administer a platelet transfusion to patients with platelet counts &lt;30,000/microL to permit treatment with the full therapeutic dose of LMWH. In patients with stabilized or resolving TE, we adjust anticoagulation dosing as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet counts &gt;30,000/microL – Full dose of LMWH</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet counts 20,000 to 30,000/microL – One-half of the dose of LMWH</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet counts &lt;20,000/microL – LMWH is held</p><p></p><p>Patients should be closely monitored on an ongoing basis for any sign of bleeding (as is the case in all patients receiving anticoagulation therapy), and the platelet count should be measured on a periodic basis. The frequency of platelet count determination is dependent upon the anticipated changes in platelet count, based on the chemotherapeutic regimen. In some cases, platelet counts may need to be measured daily, and, in others, two to three times per week is sufficient.</p><p class="headingAnchor" id="H15"><span class="h2">Asparaginase management</span><span class="headingEndMark"> — </span>Asparaginase, a key component of therapy in children with ALL, is associated with hemorrhagic and thrombotic complications (eg, cerebral sinovenous thrombosis) [<a href="#rid40">40</a>]. In the event of development of TE while receiving asparaginase, one management option is to withhold asparaginase, treat with an anticoagulant, and resume asparaginase once the child is stable and hematologic parameters normalize [<a href="#rid41">41,42</a>]. The concern with this approach is that interruption of asparaginase may negatively impact the likelihood of ALL cure [<a href="#rid43">43</a>]. An alternative approach is to use anticoagulation at either therapeutic or prophylactic doses, with or without coadministration of antithrombin, to facilitate completion of potentially curative chemotherapy. This issue is discussed separately. (See  <a class="medical medical_review" href="/d/html/1360.html" rel="external">"Antithrombin deficiency", section on 'Patients receiving asparaginase'</a> and  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Remission induction'</a>.)</p><p class="headingAnchor" id="H90885296"><span class="h2">Asymptomatic right atrial thrombosis</span><span class="headingEndMark"> — </span>The management approach for children with asymptomatic or incidental TE is as yet unclear. Right atrial thrombosis is increasingly detected by routine regular echocardiography monitoring in oncology patients, especially for patients at risk of anthracycline-induced cardiomyopathy. A systematic review suggested asymptomatic right atrial thrombosis with low-risk features (ie, small size [&lt;2 cm], nonpedunculated, and nonmobile) can be treated conservatively [<a href="#rid44">44</a>]. However, it should be noted that the critical clot size depends on the age of the child [<a href="#rid45">45</a>]. In infants and young children, smaller thrombi may be considered high risk [<a href="#rid44">44</a>].</p><p>In patients with right atrial thrombi with low-risk features, we suggest removal of the central venous catheter (CVC), if possible, and ongoing monitoring. In patients in whom the CVC cannot be removed and in those with high-risk features (ie, &gt;2 cm, pedunculated, or mobile), anticoagulation therapy may be warranted.</p><p class="headingAnchor" id="H1913114219"><span class="h1">IMPACT OF THROMBOEMBOLISM ON OUTCOME</span><span class="headingEndMark"> — </span>Children with cancer and TE have increased risk of mortality compared with children with cancer who do not experience TE [<a href="#rid3">3,46-48</a>]. In addition, children with cancer-related TE are more likely to experience subsequent TE events and/or TE-related morbidity (eg, post-thrombotic syndrome) [<a href="#rid3">3</a>]. </p><p>In a study of &gt;2000 children with acute lymphocytic leukemia (ALL), TE occurred in 6 percent and was independently associated with worse five-year overall survival (80 versus 94 percent; adjusted hazard ratio for death 2.61, 95% CI 1.62-4.22) [<a href="#rid48">48</a>]. In another study of 150 pediatric patients with cancer-related TE, the estimated TE-related mortality rate was 4.7 percent [<a href="#rid5">5</a>].</p><p>Most thrombotic events in children with cancer are not acutely life-threatening. In a study of 283 pediatric cancer patients with TE, 92 percent of events were non-life-threatening, 6 percent were life-threatening, and 2 percent were fatal [<a href="#rid2">2</a>]. </p><p>However, there may be indirect adverse consequences associated with TE, such as risk of bleeding from anticoagulation therapy and interruption or cessation of cancer treatment (asparaginase), as discussed above. (See <a class="local">'Asparaginase management'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H18"><span class="h2">Primary prevention</span><span class="headingEndMark"> — </span>The best strategies for prevention of thrombotic complications in children with cancer are to use nonpharmacologic measures (eg, encourage mobility/ambulation), clinically monitor for signs and symptoms of thrombosis, and ensure timely diagnosis and treatment when thrombosis occurs. Routine use of thromboprophylaxis does <strong>not</strong> appear to have a meaningful benefit and it exposes the child to unnecessary risk. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for routine thromboprophylaxis</strong> – We do <strong>not</strong> consider malignancy itself (with or without the presence of a central venous catheter [CVC]) to be an indication for prophylactic anticoagulation. </p><p></p><p class="bulletIndent1">Prophylactic anticoagulation may be warranted in select pediatric patients with cancer only if there are additional clinically important risk factors such as [<a href="#rid49">49</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior history of thrombosis</p><p class="bulletIndent2"><span class="glyph">•</span>Known inherited thrombophilia</p><p class="bulletIndent2"><span class="glyph">•</span>Multiple combined risk factors (eg, CVC plus asparaginase therapy plus obesity, hormonal contraceptives, or hospitalization for surgery)</p><p></p><p class="bulletIndent1">Risk prediction models have been developed for children with acute lymphoblastic leukemia (ALL) [<a href="#rid50">50,51</a>]; however, they have not been prospectively validated. </p><p></p><p class="bulletIndent1">The approach outlined here is consistent with the recommendations of the International Society on Thrombosis and Haemostasis [<a href="#rid49">49</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent1">Our suggestion against routine thromboprophylaxis for most pediatric patients with cancer is distinct from the routine use of low-dose <a class="drug drug_pediatric" data-topicid="13349" href="/d/drug information/13349.html" rel="external">unfractionated heparin</a> (UFH) flushes or infusions to maintain CVC patency, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices", section on 'Flushing and locking'</a> and  <a class="medical medical_review" href="/d/html/5911.html" rel="external">"Neonatal thrombosis: Management and outcome", section on 'Prevention of catheter-associated thrombosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of CVC placement</strong> – Practice regarding CVC placement in pediatric cancer patients may play a role in preventing TE. TE occurs less commonly in CVCs with internal lines than external tunneled lines [<a href="#rid52">52</a>]. According to guidelines from the British Society for Haematology, an internal device (eg, Port-A-Cath) is preferable to an external tunneled device (eg, Hickmann catheter) for use in pediatric cancer patients [<a href="#rid53">53</a>]. Guidelines from the Italian Association of Pediatric Hematology and Oncology advise placing CVCs on the right side of the upper venous system, leaving the tip of the catheter at the right atrial-superior vena cava junction. This is based on studies showing higher risk of TE when CVCs were placed on the left side and with the tip further into the right atrium [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of antithrombin replacement (in patients receiving asparaginase) </strong>– Practices differ among experts regarding monitoring of antithrombin (AT) levels and prophylactic AT administration in patients receiving asparaginase. This issue is discussed separately. (See  <a class="medical medical_review" href="/d/html/1360.html" rel="external">"Antithrombin deficiency", section on 'VTE prophylaxis (asparaginase)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence regarding primary thromboprophylaxis in pediatric patients with cancer</strong> – Taken together, the available clinical trial and observational data suggest that for the general pediatric oncology population, anticoagulant therapy for primary prevention of TE is unlikely to have meaningful benefit [<a href="#rid55">55-60</a>]. </p><p></p><p class="bulletIndent1">This question was addressed in a multicenter clinical trial involving 512 children and adolescents with newly diagnosed pre-B or T cell ALL who were randomly assigned to prophylactic anticoagulation (with the direct oral anticoagulant <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>) or standard care without anticoagulation [<a href="#rid59">59</a>]. All trial participants had a newly inserted CVC in place, and all were receiving planned induction chemotherapy with a glucocorticoid, <a class="drug drug_pediatric" data-topicid="12882" href="/d/drug information/12882.html" rel="external">vincristine</a>, and single or multiple doses of asparaginase, with or without an anthracycline. At one-month follow-up, symptomatic venous thrombosis occurred at similar rates in both groups (1.6 versus 2.3 percent, respectively; relative risk [RR] 0.67, 95% CI 0.19-2.23). Rates of asymptomatic venous thrombosis were also similar in both groups (11 versus 15 percent; RR 0.71, 95% CI 0.45-1.13). There were no episodes of pulmonary embolism or thrombosis-related death in either group. Episodes of nonmajor bleeding (mostly epistaxis) occurred more frequently in the apixaban group (4 versus 1 percent; RR 3.67, 95% CI 1.04-13). Episodes of major bleeding were uncommon in both groups (&lt;1 percent in each).</p><p></p><p class="bulletIndent1">An earlier quasi-randomized trial evaluated the efficacy of low molecular weight heparin (LMWH) for primary thromboprophylaxis in patients with newly diagnosed ALL [<a href="#rid60">60</a>]. In this trial, 949 children and adolescents with ALL were randomly assigned to thromboprophylaxis with LMWH, prophylactic AT, or standard care (consisting of low-dose UFH flushes to maintain CVC patency), starting on day 8 and ending on day 33 of induction chemotherapy. However, after randomization, patients were permitted to opt out of the assigned treatment or to select a different treatment option. Of the 317 patients assigned to LMWH, one-third declined the assigned treatment and instead opted for no medication, standard care (ie, UFH flushes only), or prophylactic AT therapy. Ultimately, only 216 patients received LMWH, 341 received prophylactic AT, and 372 received standard care alone. In the as-treated analysis, rates of symptomatic TE at six months were lower in patients receiving LMWH compared with standard care (3.2 versus 6.7 percent), but the difference was not statistically significant (odds ratio 0.47, 95% CI 0.20-1.09). Rates of TE were similar in the LMWH and AT groups (3.2 and 2.6 percent, respectively). Major bleeding events were rare in all three groups (1 event in the LMWH group, 3 events in the AT group, and 4 events in the standard care group). Estimated five-year event-free survival was similar in all three groups (85 percent in the LMWH group, 83 percent in the AT group, and 86 percent in the standard care group). Important limitations of this trial include lack of blinding and the high rate of crossover from the LMWH arm to other treatment arms, resulting in loss randomization. The high refusal rate illustrates the poor acceptability of daily LMWH injections as a routine part of care for patients with newly diagnosed ALL. This is also illustrated by the trial's relatively low enrollment (ie, of 1526 patients who were eligible for the trial, 577 [38 percent] declined because they did not want to receive daily subcutaneous injections). </p><p></p><p class="headingAnchor" id="H19"><span class="h2">Prevention of recurrent thrombosis</span><span class="headingEndMark"> — </span>Based upon studies in pediatric cancer patients and indirect data from adult cancer patients, our approach to secondary prophylaxis is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have been diagnosed with TE and are receiving therapeutic anticoagulation, we suggest extending anticoagulation if there are ongoing clinically important thrombotic risk factors, such as the use of asparaginase. The exception is the presence of an indwelling CVC. We generally discontinue anticoagulation even if the CVC remains in place for a prolonged period of time (eg, two years or greater), provided other significant risk factors (eg, asparaginase) are resolved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We offer prophylactic anticoagulation to patients with relapsed cancer who were previously diagnosed with TE in association with their primary cancer therapy if they will be receiving subsequent cancer therapy with similar thrombotic risk</p><p></p><p>Use of prophylactic anticoagulation in these circumstances is based on the observation that the recurrence rate of TE is twofold greater in children with cancer compared with those without cancer [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3358060808"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117261.html" rel="external">"Society guideline links: Thrombotic diseases in infants and children"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Children with cancer are at increased risk for thrombosis and thromboembolism (TE) compared with the general pediatric population. The overall reported prevalence ranges from 4 to 8 percent. The rates of TE vary for specific malignancies, with the highest risk of TE in children with acute lymphocytic leukemia (ALL), followed by sarcoma and lymphoma, and the lowest risk in those with brain tumors. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of TE in children with cancer are similar to those seen in children without cancer. Clinical manifestations vary depending upon the location and extent of the thrombus, acuteness of the event, and age of the patient. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion and diagnosis</strong> – In children with cancer, the presentation of TE events can overlap with that of other cancer-associated problems. Clinicians who treat cancer patients should maintain a high index of suspicion for TE. The diagnosis of TE is confirmed by imaging studies (eg, duplex ultrasound for suspected venous thrombosis, computed tomography pulmonary angiography for suspected pulmonary embolism, contrast-enhanced magnetic resonance imaging for suspected cerebral venous thrombosis or arterial stroke). The diagnostic approach is the same as for children without cancer, as discussed separately. (See  <a class="medical medical_review" href="/d/html/5918.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management of cancer-related TE is challenging because children with cancer are at risk for both thrombus progression and recurrence, as well as bleeding due to chemotherapy-related thrombocytopenia and coagulopathy. Our approach is as follows (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of agent</strong> – For most children with cancer-related TE, we suggest low molecular weight heparin (LMWH) rather than other agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The advantages and disadvantages of LMWH and other agents are outlined in the table and discussed in greater detail separately  (<a class="graphic graphic_table graphicRef114581" href="/d/graphic/114581.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Anticoagulant agents'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing </strong>– The initial dosing of LMWH and further dose adjustment based on anti-Xa levels are the same as those used in the general pediatric population  (<a class="graphic graphic_table graphicRef64075" href="/d/graphic/64075.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Low molecular weight heparin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration </strong>– The usual duration of anticoagulation is at least three months. Extended anticoagulation may be warranted if there are ongoing clinically important thrombotic risk factors (eg, use of asparaginase). (See <a class="local">'Prevention of recurrent thrombosis'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of anticoagulation in patients with thrombocytopenia</strong> – Patients receiving anticoagulation therapy should have platelet counts monitored regularly (ie, daily to twice a week, depending on the chemotherapeutic regimen). For patients with thrombocytopenia during the initial acute management of TE, we suggest platelet transfusion to maintain platelet count ≥30,000/microL rather than holding or reducing the dose of LMWH (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This permits treatment with the full therapeutic dose of LMWH, which is important during the acute phase of management. By contrast, for patients who have thrombocytopenia while on LMWH after the acute phase (ie, once the TE is stabilized or resolving), we suggest adjusting the LMWH dose rather than giving platelet transfusions (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We adjust the LMWH dose as follows (see <a class="local">'Management of anticoagulation in patients with thrombocytopenia'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Platelet counts &gt;30,000/microL – Full dose of LMWH</p><p class="bulletIndent3"><span class="glyph">-</span>Platelet counts 20,000 to 30,000/microL – One-half the dose of LMWH</p><p class="bulletIndent3"><span class="glyph">-</span>Platelet counts &lt;20,000/microL – LMWH is held</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asparaginase management</strong> – The approach to managing TE in patients receiving asparaginase therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1360.html" rel="external">"Antithrombin deficiency", section on 'Patients receiving asparaginase'</a> and  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'Complications of ALL/LBL and treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of asymptomatic right atrial thrombus</strong> – In patients with asymptomatic right atrial thrombus with low-risk features (ie, &lt;2 cm, nonpedunculated, and nonmobile), we suggest conservative management rather than anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Conservative management consists of removal of the central venous catheter (CVC), if present, and monitoring. Therapeutic anticoagulation is reasonable for patients in whom the CVC cannot be removed and those with high-risk features (ie, &gt;2 cm, pedunculated, or mobile). (See <a class="local">'Asymptomatic right atrial thrombosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The best strategies for prevention of thrombotic complications in children with cancer are to use nonpharmacologic measures (eg, encourage mobility/ambulation), clinically monitor for signs and symptoms of thrombosis, and ensure timely diagnosis and treatment when thrombosis occurs. Routine use of thromboprophylaxis does <strong>not</strong> appear to have a meaningful benefit and it exposes the child to unnecessary risk. Prophylactic anticoagulation may be warranted in select children with cancer only if there are additional clinically important risk factors such as a history of recurrent thrombosis, known inherited thrombophilia, or multiple combined risk factors (eg, CVC plus asparaginase therapy plus obesity, hormonal contraceptives, and/or hospitalization for surgery). (See <a class="local">'Prevention'</a> above and  <a class="medical medical_review" href="/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Approach to VTE prophylaxis'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008; 51:792.</a></li><li><a class="nounderline abstract_t">Pelland-Marcotte MC, Pole JD, Kulkarni K, et al. Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study. Thromb Haemost 2018; 118:1646.</a></li><li><a class="nounderline abstract_t">Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124:1001.</a></li><li><a class="nounderline abstract_t">O'Brien SH, Klima J, Termuhlen AM, Kelleher KJ. Venous thromboembolism and adolescent and young adult oncology inpatients in US children's hospitals, 2001 to 2008. J Pediatr 2011; 159:133.</a></li><li><a class="nounderline abstract_t">Dhariwal N, Gollamudi VRM, Sangeetha KP, et al. Pediatric cancer-associated thrombosis: Analysis from a tertiary care cancer center in India. Pediatr Blood Cancer 2023; 70:e30096.</a></li><li><a class="nounderline abstract_t">Mizrahi T, Leclerc JM, David M, et al. ABO Group as a Thrombotic Risk Factor in Children With Acute Lymphoblastic Leukemia: A Retrospective Study of 523 Patients. J Pediatr Hematol Oncol 2015; 37:e328.</a></li><li><a class="nounderline abstract_t">Athale UH, Mizrahi T, Laverdière C, et al. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation. Pediatr Blood Cancer 2018; 65:e26938.</a></li><li><a class="nounderline abstract_t">Prasca S, Carmona R, Ji L, et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res 2018; 165:44.</a></li><li><a class="nounderline abstract_t">Spavor M, Halton J, Dietrich K, et al. Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model. Thromb Res 2016; 144:27.</a></li><li><a class="nounderline abstract_t">Athale UH, Nagel K, Khan AA, Chan AK. Thromboembolism in children with lymphoma. Thromb Res 2008; 122:459.</a></li><li><a class="nounderline abstract_t">Gartrell J, Kaste SC, Sandlund JT, et al. The association of mediastinal mass in the formation of thrombi in pediatric patients with non-lymphoblastic lymphomas. Pediatr Blood Cancer 2020; 67:e28057.</a></li><li><a class="nounderline abstract_t">Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. Thromb Res 2006; 118:137.</a></li><li><a class="nounderline abstract_t">Schiavetti A, Foco M, Ingrosso A, et al. Venous thrombosis in children with solid tumors. J Pediatr Hematol Oncol 2008; 30:148.</a></li><li><a class="nounderline abstract_t">Paz-Priel I, Long L, Helman LJ, et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007; 25:1519.</a></li><li><a class="nounderline abstract_t">Athale U, Cox S, Siciliano S, Chan AK. Thromboembolism in children with sarcoma. Pediatr Blood Cancer 2007; 49:171.</a></li><li><a class="nounderline abstract_t">Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998; 133:770.</a></li><li><a class="nounderline abstract_t">Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006; 24:4575.</a></li><li><a class="nounderline abstract_t">Albisetti M, Kellenberger CJ, Bergsträsser E, et al. Port-a-cath-related thrombosis and postthrombotic syndrome in pediatric oncology patients. J Pediatr 2013; 163:1340.</a></li><li><a class="nounderline abstract_t">Deitcher SR, Gajjar A, Kun L, Heideman RL. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004; 145:848.</a></li><li><a class="nounderline abstract_t">Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999; 158 Suppl 3:S143.</a></li><li><a class="nounderline abstract_t">Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Rev Hematol 2013; 6:599.</a></li><li><a class="nounderline abstract_t">Knöfler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines. Eur J Pediatr 1999; 158 Suppl 3:S147.</a></li><li><a class="nounderline abstract_t">Tabori U, Beni-Adani L, Dvir R, et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004; 43:633.</a></li><li><a class="nounderline abstract_t">Athale UH, Chan AK. Thromboembolic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007; 33:416.</a></li><li><a class="nounderline abstract_t">Schoot RA, Kremer LC, van de Wetering MD, van Ommen CH. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters. Cochrane Database Syst Rev 2013; :CD009160.</a></li><li><a class="nounderline abstract_t">Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800.</a></li><li><a class="nounderline abstract_t">Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128:313.</a></li><li><a class="nounderline abstract_t">Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161:71.</a></li><li><a class="nounderline abstract_t">Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439.</a></li><li><a class="nounderline abstract_t">Nohe N, Flemmer A, Rümler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158 Suppl 3:S134.</a></li><li><a class="nounderline abstract_t">Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109:85.</a></li><li><a class="nounderline abstract_t">Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146.</a></li><li><a class="nounderline abstract_t">Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123.</a></li><li><a class="nounderline abstract_t">Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.</a></li><li><a class="nounderline abstract_t">Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5:927.</a></li><li><a class="nounderline abstract_t">Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2:3292.</a></li><li class="breakAll">ClinicalTrials.gov Identifier: NCT02369653. A study of the safety and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with asparaginase. Revised March 8, 2022. US National Library of Medicine. https://clinicaltrials.gov/ct2/show/results/NCT02369653 (Accessed on February 15, 2023).</li><li><a class="nounderline abstract_t">Palumbo JS, Lensing AWA, Brandão LR, et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv 2022; 6:5821.</a></li><li><a class="nounderline abstract_t">Barg AA, Levy-Mendelovich S, Gilad O, et al. Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data. Pediatr Blood Cancer 2022; 69:e29888.</a></li><li><a class="nounderline abstract_t">Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988; 38:127.</a></li><li><a class="nounderline abstract_t">Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in pediatric and adult patients with acute lymphoblastic leukemia treated on the Dana-Farber Cancer Institute (DFCI) Consortium protocols. Blood 2009; 114:3073.</a></li><li><a class="nounderline abstract_t">Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol 2010; 149:410.</a></li><li><a class="nounderline abstract_t">Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211.</a></li><li><a class="nounderline abstract_t">Yang JY, Williams S, Brandão LR, Chan AK. Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach. Blood Coagul Fibrinolysis 2010; 21:301.</a></li><li><a class="nounderline abstract_t">Yang JY, Williams S, Brandão LR, et al. Neonatal and childhood right atrial thrombosis: critical clot size. Blood Coagul Fibrinolysis 2013; 24:458.</a></li><li><a class="nounderline abstract_t">Tuckuviene R, Ranta S, Albertsen BK, et al. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. J Thromb Haemost 2016; 14:485.</a></li><li><a class="nounderline abstract_t">Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood 2018; 131:2475.</a></li><li><a class="nounderline abstract_t">Pelland-Marcotte MC, Kulkarni K, Athale UH, et al. Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP-C. Am J Hematol 2021; 96:796.</a></li><li><a class="nounderline abstract_t">Tullius BP, Athale U, van Ommen CH, et al. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16:175.</a></li><li><a class="nounderline abstract_t">Mitchell L, Lambers M, Flege S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115:4999.</a></li><li><a class="nounderline abstract_t">Mateos MK, Trahair TN, Mayoh C, et al. Clinical predictors of venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Blood 2016; :1182.</a></li><li><a class="nounderline abstract_t">Mangum DS, Verma A, Weng C, et al. A comparison of central lines in pediatric oncology patients: Early removal and patient centered outcomes. Pediatr Blood Cancer 2013; 60:1890.</a></li><li><a class="nounderline abstract_t">Sibson KR, Biss TT, Furness CL, et al. BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy. Br J Haematol 2018; 180:511.</a></li><li><a class="nounderline abstract_t">Giordano P, Saracco P, Grassi M, et al. Recommendations for the use of long-term central venous catheter (CVC) in children with hemato-oncological disorders: management of CVC-related occlusion and CVC-related thrombosis. On behalf of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Ann Hematol 2015; 94:1765.</a></li><li><a class="nounderline abstract_t">Ruud E, Holmstrøm H, De Lange C, et al. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. Acta Paediatr 2006; 95:1053.</a></li><li><a class="nounderline abstract_t">Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001; 12:367.</a></li><li><a class="nounderline abstract_t">Meister B, Kropshofer G, Klein-Franke A, et al. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50:298.</a></li><li><a class="nounderline abstract_t">Pelland-Marcotte MC, Tole S, Pechlivanoglou P, Brandão LR. Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis. Thromb Haemost 2019; 119:2034.</a></li><li><a class="nounderline abstract_t">O'Brien SH, Rodriguez V, Lew G, et al. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol 2024; 11:e27.</a></li><li><a class="nounderline abstract_t">Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica 2019; 104:756.</a></li></ol></div><div id="topicVersionRevision">Topic 6236 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18798556" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30103249" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19736261" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353248" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Venous thromboembolism and adolescent and young adult oncology inpatients in US children's hospitals, 2001 to 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36401555" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pediatric cancer-associated thrombosis: Analysis from a tertiary care cancer center in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25851553" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ABO Group as a Thrombotic Risk Factor in Children With Acute Lymphoblastic Leukemia: A Retrospective Study of 523 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29334169" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567586" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27270219" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18237767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thromboembolism in children with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31736198" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The association of mediastinal mass in the formation of thrombi in pediatric patients with non-lymphoblastic lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039698" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thromboembolic complications in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376268" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Venous thrombosis in children with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442994" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thromboembolic events in children and young adults with pediatric sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16991135" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thromboembolism in children with sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9842042" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008698" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Catheter-related deep venous thrombosis and other catheter complications in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992671" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Port-a-cath-related thrombosis and postthrombotic syndrome in pediatric oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580217" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinically evident venous thromboembolic events in children with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650855" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125523" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Thrombosis in pediatric cancer: identifying the risk factors to improve care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650856" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15390288" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk of venous thromboembolism in pediatric patients with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17525899" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thromboembolic complications in pediatric hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026801" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10366369" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774496" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11954754" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Low molecular weight heparin in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753240" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The use of low molecular weight heparin in pediatric patients: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650853" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12706636" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853587" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699480" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315277" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570602" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482766" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482766" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36006613" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35856619" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rivaroxaban treatment among children with cancer-associated thromboembolism: Real-world data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275903" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cerebrovascular complications of L-asparaginase therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The frequency and management of asparaginase-related thrombosis in pediatric and adult patients with acute lymphoblastic leukemia treated on the Dana-Farber Cancer Institute (DFCI) Consortium protocols</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20201945" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222362" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305543" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632382" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Neonatal and childhood right atrial thrombosis: critical clot size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26707629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661787" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33848369" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP-C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29178421" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20339086" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical predictors of venous thromboembolism during therapy for childhood acute lymphoblastic leukemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23868811" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A comparison of central lines in pediatric oncology patients: Early removal and patient centered outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29384193" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26300457" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recommendations for the use of long-term central venous catheter (CVC) in children with hemato-oncological disorders: management of CVC-related occlusion and CVC-related thrombosis. On behalf of the coagulation defects working group and the supportive therapy working group of the Italian Association of Pediatric Hematology and Oncology (AIEOP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16938749" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11505079" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443678" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600808" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37980924" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30262570" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
